Stock NAVB NAVIDEA BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Navidea Biopharmaceuticals, Inc.

Equities

NAVB

US63937X2027

Delayed OTC Markets
Other stock markets
 09:37:15 2024-06-24 EDT 		5-day change 1st Jan Change
0.06 USD +5,999,900.00% Intraday chart for Navidea Biopharmaceuticals, Inc. 0.00% -100.00%
06-21 Navidea Biopharmaceuticals, Inc. Announces Board Resignations CI
2023 Navidea Biopharmaceuticals, Inc. announced that it has received $0.75 million in funding CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision
MT
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Navidea Biopharmaceuticals Confirms Rejection of ProPhase Labs' Proposal to Buy Some of Its Assets
MT
ProPhase Labs Says Offer to Acquire Certain Navidea Biopharmaceuticals' Assets Rejected
MT
ProPhase Labs, Inc. cancelled the acquisition of Certain Assets from Navidea Biopharmaceuticals, Inc. for $7 million.
CI
Navidea Biopharmaceuticals Notified of Non-Compliance With NYSE American Listing Rule
MT
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Navidea Biopharmaceuticals, Meilleur Technologies Sign License Deal for Alzheimer's Disease Diagnosis Agent
MT
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694
CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Cancer Immunotherapy Pipeline
CI
Navidea Biopharmaceuticals, Inc. Announces 50th Participant Enrolled in the its Phase 3 Trial in Rheumatoid Arthritis
CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Navidea Biopharmaceuticals Tapped for Presentation at November Cancer Conference
MT
Navidea Biopharmaceuticals, Inc. Announces Results from the Completed NAV3-31 Phase 2B Clinical Study as Well as the Preliminary Results of Its Ongoing NAV3-32 Phase 2B Study At Annual Meeting of the American College of Rheumatology
CI
Navidea Biopharmaceuticals, Inc. Opens Nine New Sites in Its Pivotal Phase 3 Trial in Rheumatoid Arthritis
CI
Navidea Biopharmaceuticals, Inc. Terminates Memorandum of Understanding with Jubilant Radiopharma
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAVB Stock
  4. News Navidea Biopharmaceuticals, Inc.
  5. Highlights